ライフサイエンスコーパス: parenteral nutrition

1 nutritional deficit for 1 week in ICU (late parenteral nutrition).

2 stinal failure experiencing complications of parenteral nutrition.

3 d weight loss while receiving long term home parenteral nutrition.

4 reatening complications related to long-term parenteral nutrition.

5 y ill neonates, and patients receiving total parenteral nutrition.

6 enal replacement therapy observed with early parenteral nutrition.

7 t length of stay in comparison with standard parenteral nutrition.

8 63% of the extra nitrogen intake from early parenteral nutrition.

9 nservatively with dietary measures and total parenteral nutrition.

10 ring intensive insulin therapy than is total parenteral nutrition.

11 nal and liver failure were gastroschisis and parenteral nutrition.

12 al and special population patients receiving parenteral nutrition.

13 Fluoride toxicity may be a concern in parenteral nutrition.

14 ented parenteral nutrition is better than no parenteral nutrition.

15 n insulin, intravenous amino acids, and full parenteral nutrition.

16 quality of life for patients living on home parenteral nutrition.

17 e typically administered with standard total parenteral nutrition.

18 ion for any patient permanently dependent on parenteral nutrition.

19 nal failure and 15% to 40% of adults on home parenteral nutrition.

20 more efficacious and poses lower risks than parenteral nutrition.

21 post-surfactant and increasing early use of parenteral nutrition.

22 gs: hemodialysis, cancer treatment, and home parenteral nutrition.

23 infants who are typically supported by total parenteral nutrition.

24 U) is clinically superior to providing early parenteral nutrition.

25 U was clinically superior to providing early parenteral nutrition.

26 c dependence on central venous catheters for parenteral nutrition.

27 e a promising therapy to allow autonomy from parenteral nutrition.

28 to acquire intestinal failure requiring home parenteral nutrition.

29 odds ratio [95% confidence interval]): total parenteral nutrition (2.79 [1.26-6.17]), dialysis depend

30 vs 17.5%, RR: 0.2, CI: 0.09-0.5), and total parenteral nutrition (3.9% vs 22.5%, RR: 0.2, CI: 0.07-0

31 17.5%; RR, 0.2 [95% CI, .09-.5]), and total parenteral nutrition (3.9% vs 22.5%; RR, 0.2 [95% CI, .0

32 P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P<0.001

33 3%), prolonged drainage (67.8%), and enteral/parenteral nutrition (54.7%).

34 ar portion of the patients require long-term parenteral nutrition (86% vs. 84%) or have undergone int

35 Secondary outcomes included dependence on parenteral nutrition 90 days postoperatively and length

36 ared with 18.5% in the group receiving early parenteral nutrition (adjusted odds ratio, 0.48; 95% con

37 interval, 1.8 to 148.1) and receipt of total parenteral nutrition (adjusted odds ratio, 9.2; 95% conf

38 Total parenteral nutrition administration was associated with

39 s received olive oil-based lipid emulsion in parenteral nutrition (age 46 +/- 19 yrs, body mass index

40 al of 49 patients received soybean oil-based parenteral nutrition (age 51 +/- 15 yrs, body mass index

41 Early parenteral nutrition also increased the volume of adipos

42 s indicate that copper requirements in total parenteral nutrition amount to 0.3 mg/day in the adult.

43 ation and patient survival, both on extended parenteral nutrition and after transplantation, have imp

44 inct physiological differences between total parenteral nutrition and enteral nutrition that are more

45 Survivors are off parenteral nutrition and have demonstrated significant g

46 eatment included application of colchicines, parenteral nutrition and magnesium substitution, antiper

47 e's use in critically ill patients requiring parenteral nutrition and new data reveal safety and effi

48 do not, and why some patients tolerate total parenteral nutrition and others develop liver dysfunctio

49 el syndrome (SBS) is now possible because of parenteral nutrition and small bowel transplantation.

50 d over the past few decades, especially with parenteral nutrition and surgical repair.

51 illus atrophy by the administration of total parenteral nutrition, and a model of villus hypertrophy

52 utaneous drainage, antibiotics at discharge, parenteral nutrition, and an extended hospital length of

53 tidisciplinary approach to the management of parenteral nutrition, and aseptic catheter techniques to

54 eservation of venous access, "hepatosparing" parenteral nutrition, and avoidance of liver sepsis are

55 mined include patient survival, weaning from parenteral nutrition, and need for intestinal transplant

56 itive function, decreased functional status, parenteral nutrition, and pressure ulcers.

57 iglycerides, therapeutic paracentesis, total parenteral nutrition, and somatostatins.

58 functional compromise induced by fasting and parenteral nutrition, and the enhanced adaptive capacity

59 support various beliefs about the utility of parenteral nutrition, and then to critically evaluate th

60 gs (hemodialysis, cancer treatment, and home parenteral nutrition), antimicrobial lock solutions are

61 However, amino acids in parenteral nutrition are effective for increasing protei

62 ection was 10.7% in the group receiving late parenteral nutrition, as compared with 18.5% in the grou

63 s 6.5+/-0.4 days in the group receiving late parenteral nutrition, as compared with 9.2+/-0.8 days in

64 Parenteral nutrition-associated liver disease (PNALD) is

65 Parenteral nutrition-associated liver disease (PNALD) is

66 ous lipid emulsion (ILE) in the treatment of parenteral nutrition-associated liver disease (PNALD).

67 If high survival could be achieved and if parenteral nutrition-associated liver disease were rever

68 titis, primary sclerosing cholangitis, total parenteral nutrition-associated liver disease, and cysti

69 ns, phytosterols may promote liver injury in parenteral nutrition-associated liver disease.

70 All surviving patients weaned-off total parenteral nutrition at a median time of 32 days and 90%

71 ose into the systemic circulation with total parenteral nutrition at rates that approximate usual pos

72 nitiation of enteral (oral or tube feeds) or parenteral nutrition; avoidance of any unwanted hypocarb

73 Enteral or parenteral nutrition before, during, and after CABG may

74 tation of these amino acids with enteral and parenteral nutrition before, during, and after surgery m

75 All children were weaned from parenteral nutrition between 31 and 85 d posttransplanta

76 ailure and life-threatening complications of parenteral nutrition, but it is still plagued by high le

77 se receiving omega-3 fatty acid supplemented parenteral nutrition, but results were strongly influenc

78 The cost of parenteral nutrition compared to intestinal transplantat

79 tudy of a randomized controlled trial (Early Parenteral Nutrition Completing Enteral Nutrition in Adu

80 pecified analysis from this trial, the Early Parenteral Nutrition Completing Enteral Nutrition in Adu

81 with insulin did not lower glucagon, whereas parenteral nutrition containing amino acids increased gl

82 Parenteral nutrition containing soybean oil-based (Intra

83 The administration of parenteral nutrition containing soybean oil-based and ol

84 n = 61) or early parenteral nutrition (early parenteral nutrition, control) by jugular vein catheter

85 ature infants, patients with long-term total parenteral nutrition, Crohn's disease, cystic fibrosis,

86 are important adjuncts to the elimination of parenteral nutrition dependence and need for intestinal

87 Patients who remained parenteral nutrition dependent were more likely to have

88 A total of 500 patients with total parenteral nutrition-dependent catastrophic and chronic

89 once biochemical cholestasis is detected in parenteral nutrition-dependent patients is recommended.

90 ajor cause of morbidity and mortality in the parenteral nutrition-dependent population.

91 sed for augmentation of energy absorption in parenteral nutrition-dependent subjects with short bowel

92 tral line, and had 1 additional risk factor (parenteral nutrition, dialysis, surgery, pancreatitis, s

93 The timing of parenteral nutrition did not affect the incidence of AKI

94 Early parenteral nutrition did not affect the time course of c

95 Early parenteral nutrition did not prevent the pronounced wast

96 d that omega-3 fatty acid supplementation of parenteral nutrition does not improve mortality, infecti

97 sed pulmonary risk, routine total enteral or parenteral nutrition does not reduce risk (1 meta-analys

98 In conclusion, early parenteral nutrition does not seem to impact AKI inciden

99 mental changes in the nature and practice of parenteral nutrition during the review period, there hav

100 ntion) by nasojejunal tube (n = 61) or early parenteral nutrition (early parenteral nutrition, contro

101 However, energy provision with parenteral nutrition, either instead of or supplemental

102 atic review assessed 37 trials that compared parenteral nutrition, enteral nutrition, or nutritional

103 e randomly assigned to EEN (n = 61) or early parenteral nutrition (EPN, n = 62) in addition to an ora

104 attributable to increasing complications of parenteral nutrition, especially infectious complication

105 efine the parameters that best predict total parenteral nutrition failure and the unique mechanisms t

106 complicated by short gut syndrome and total parenteral nutrition failure.

107 children to investigate whether withholding parenteral nutrition for 1 week (i.e., providing late pa

108 In critically ill children, withholding parenteral nutrition for 1 week in the ICU was clinicall

109 placement therapy, compared with withholding parenteral nutrition for 1 week.

110 an or equal to 13, expected to require total parenteral nutrition for at least 5 days.

111 r a recipient of CLDILTx, currently on total parenteral nutrition for late fistula.

112 ntilated within 48 hours, received exclusive parenteral nutrition for more than or equal to 5 days, a

113 with type 2 diabetes and a child on chronic parenteral nutrition for short bowel syndrome.

114 Patients with SBS who suffer from IF require parenteral nutrition for survival, but long-term parente

115 ased parenteral nutrition or olive oil-based parenteral nutrition for up to 28 days.

116 35%) of those who were alive at 28 days were parenteral nutrition free.

117 76%, p = .03), and a decrease in patients on parenteral nutrition (from 26% to 21%, p = .04).

118 scharge from the ICU at any time in the late-parenteral-nutrition group (adjusted hazard ratio, 1.23;

119 d with soybean oil-based and olive oil-based parenteral nutrition had a similar length of stay (47 +/

120 ndomized trials have found that supplemental parenteral nutrition has a deleterious effect in compari

121 Parenteral nutrition has achieved extended success for t

122 Parenteral nutrition has been associated with metabolic

123 The indications for parenteral nutrition have been examined over the past ye

124 oeconomic status, sex, and number of days on parenteral nutrition, higher stressful life events score

125 Home parenteral nutrition (HPN) and intestinal transplantatio

126 intestinal macronutrient absorption and home parenteral nutrition (HPN) dependence in SBS patients wi

127 We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the

128 ts with CIPO with end-stage disease and home parenteral nutrition (HPN)-associated complications.

129 testinal failure (IF) and dependency on home parenteral nutrition (HPN).

130 A recent study showed that intradialytic parenteral nutrition (IDPN) improves whole-body protein

131 Intradialytic parenteral nutrition (IDPN) reverses the net negative wh

132 Intradialytic parenteral nutrition (IDPN), with or without exercise, h

133 Whether early versus late parenteral nutrition impacts the incidence and recovery

134 -abdominal abscess in 23 patients, and total parenteral nutrition in 74 (36%).

135 tinal absorption at the time of weaning from parenteral nutrition in a series of children after intes

136 ntration greater than 7 g/dl; (3) do not use parenteral nutrition in adequately nourished critically

137 trials have questioned the benefit of early parenteral nutrition in adults.

138 ed trials of omega-3 fatty acid supplemented parenteral nutrition in critically ill adult patients ad

139 Use of early parenteral nutrition in critically ill patients in whom

140 GLP-2R signaling reduces the requirement for parenteral nutrition in human subjects with short-bowel

141 Enteral nutrition may be more effective than parenteral nutrition in limiting proteolysis and produci

142 guidelines recommend the use of enteral over parenteral nutrition in patients undergoing gastrointest

143 gonlike peptide 2 that reduces dependence on parenteral nutrition in patients with short bowel syndro

144 a specialized diet will reduce the need for parenteral nutrition in patients with short bowel syndro

145 l nutrition for 1 week (i.e., providing late parenteral nutrition) in the pediatric intensive care un

146 l measure in humans (such as those receiving parenteral nutrition) in whom choline deficiency is susp

147 The administration of parenteral nutrition, including lipid emulsion (LE), to

148 to B (stable in C), and days on combined and parenteral nutrition increased progressively.

149 Furthermore, early parenteral nutrition increased the amount of adipose tis

150 with intestinal failure expected to require parenteral nutrition indefinitely.

151 cholangitis, cholestasis of pregnancy, total parenteral nutrition-induced cholestasis, and drug-induc

152 In the group that received late parenteral nutrition, infusing amino acids after the fir

153 meliorates hepatic steatosis associated with parenteral nutrition infusion.

154 There are no convincing data that parenteral nutrition is beneficial in severely malnouris

155 but it is unknown if glutamine-supplemented parenteral nutrition is better than no parenteral nutrit

156 Parenteral nutrition is central to the care of very imma

157 not uniformly been able to demonstrate that parenteral nutrition is efficacious in acute pancreatiti

158 ong-term survival of patients with continued parenteral nutrition is higher than after intestinal tra

159 The relative safety of long-term parenteral nutrition is reconfirmed.

160 Total parenteral nutrition led to a loss of EBF, and this was

161 Parenteral nutrition may help to meet many of the nutrit

162 nteral nutrition for survival, but long-term parenteral nutrition may lead to complications such as c

163 o popular belief, appropriately administered parenteral nutrition may provide similar or more benefit

164 bile salts, as occurs during starvation and parenteral nutrition, may have a detrimental effect on m

165 ough there is evidence to suggest that total parenteral nutrition more effectively spares protein in

166 These factors may make total parenteral nutrition more efficacious, at least initiall

167 Parenteral nutrition needs attention to detail if it is

168 teral nutrition produces fewer problems than parenteral nutrition; no data suggest that either modali

169 ortality was higher in patients who received parenteral nutrition (odds ratio 2.61 [1.3, 5.3], p = .0

170 dependence on enteral tube feeding or total parenteral nutrition [odds ratio (OR) 4.30, 95% confiden

171 : odds ratio, 2.65; 95% CI, 1.93-3.63; total parenteral nutrition: odds ratio, 3.27; 95% CI, 2.24-4.7

172 The effect of early parenteral nutrition on clinical outcomes in critically

173 assess the effect of early administration of parenteral nutrition on muscle volume and composition by

174 (stratified by type of nutritional support [parenteral nutrition on or off] and pre-study total dail

175 n therapy in inpatients receiving enteral or parenteral nutrition or both.

176 were randomized to either soybean oil-based parenteral nutrition or olive oil-based parenteral nutri

177 ial in adult inpatients receiving enteral or parenteral nutrition (or both) who required subcutaneous

178 fluoride parenterally would prevent or treat parenteral nutrition osteopenia.

179 considerable amount of work in the field of parenteral nutrition over the last year.

180 The use of total parenteral nutrition (p = 0.03), longer duration of anti

181 rase and alkaline phosphatase than was early parenteral nutrition (P=0.001 and P=0.04, respectively),

182 echanical ventilatory support than was early parenteral nutrition (P=0.001), as well as a smaller pro

183 For the 723 patients receiving early parenteral nutrition, parenteral nutrition was initiated

184 whereas for the 717 patients receiving late parenteral nutrition, parenteral nutrition was not provi

185 Use of alternative IV fat emulsions in parenteral nutrition, particularly olive and fish oil, w

186 When compared with lipid-free parenteral nutrition, patients who received fish oil had

187 Seven were put on total parenteral nutrition plus octreotide.

188 Sixteen patients were on parenteral nutrition (PN) after 74 PN months (range, 2.5

189 Discontinuation of parenteral nutrition (PN) after reSTEP was achieved in 6

190 Compounding pharmacies often prepare parenteral nutrition (PN) and must adhere to rigorous st

191 me (SBS) who were "permanently" dependent on parenteral nutrition (PN) and to identify possible progn

192 Long-term parenteral nutrition (PN) carries the risk of progressiv

193 The impact of dilatation on parenteral nutrition (PN) dependence and survival has no

194 not routinely added that should be part of a parenteral nutrition (PN) formula?

195 Standard trace element-supplemented neonatal parenteral nutrition (PN) has a high manganese content a

196 lant sterols, including stigmasterol, during parenteral nutrition (PN) have been linked with serum bi

197 ded and the means of delivery in patients on parenteral nutrition (PN) have been unclear.

198 Parenteral nutrition (PN) impairs mucosal immunity and i

199 IFALD) is a common complication of long-term parenteral nutrition (PN) in children and adults.

200 Efforts to optimize early parenteral nutrition (PN) in extremely low-birth-weight

201 Parenteral nutrition (PN) increases risks of infections

202 The use of early parenteral nutrition (PN) is one potential strategy to a

203 Parenteral nutrition (PN) is still widely preferred to e

204 Parenteral nutrition (PN) is the main treatment for inte

205 ILE based on soybean oil administered with parenteral nutrition (PN) may contribute to its etiology

206 testinal failure (IF) treated with long-term parenteral nutrition (PN) may present with low bone mine

207 arly enteral nutrition (EN) may benefit from parenteral nutrition (PN) provided within 24 hours of IC

208 For children and adults on parenteral nutrition (PN) the main mortality risk factor

209 em cell transplantation (HSCT) often require parenteral nutrition (PN) to optimize caloric intake.

210 rol concentrations are an untoward effect of parenteral nutrition (PN) with vegetable oil-based lipid

211 Of this group, 41% were receiving parenteral nutrition (PN), 41% were receiving enteral fe

212 Total parenteral nutrition (PN), including fat administered as

213 raphy or ultrasonography), laboratory tests, parenteral nutrition (PN), peripherally inserted central

214 ns (ILEs) are used as a monotherapy to treat parenteral nutrition (PN)-associated liver disease and p

215 Infants with intestinal failure who are parenteral nutrition (PN)-dependent may develop cholesta

216 ed intravenously to all patients who require parenteral nutrition (PN).

217 rving growth and development with the use of parenteral nutrition (PN).

218 ldren with intestinal failure (IF) depend on parenteral nutrition (PN).

219 habilitation that necessitate chronic use of parenteral nutrition (PN).

220 ection for mesenteric infarction may require parenteral nutrition (PN).

221 with short bowel syndrome (SBS) who require parenteral nutrition (PN).

222 ical illness and are allegedly aggravated by parenteral nutrition (PN).

223 Patients received total parenteral nutrition prepared either with a lipid emulsi

224 Late parenteral nutrition prevented infections and accelerate

225 Calorie delivery from enteral nutrition, parenteral nutrition, propofol, and dextrose containing

226 ne therapy/apnea of prematurity, duration of parenteral nutrition, pulmonary hemorrhage, and white ma

227 Early parenteral nutrition reduced the quality of the muscle t

228 t multivisceral transplantation due to total parenteral nutrition-related liver disease.

229 omography severity index score at admission, parenteral nutrition requirement before or after radiolo

230 omputing anatomy of reconstructed gut, total parenteral nutrition requirements, cause of GF, and seru

231 lutamine and diet in hopes of reducing their parenteral nutrition requirements.

232 e cancer setting, and $78513.83 for the home parenteral nutrition setting per CLABSI episode prevente

233 ent setting, and a 92.73% chance in the home parenteral nutrition setting.

234 Total parenteral nutrition should be considered only in cases

235 The use of parenteral nutrition should be limited within the first

236 Enteral feeding tubes and parenteral nutrition should not be used routinely.

237 Glutamine supplementation of parenteral nutrition solutions may reduce the infectious

238 rtage of injectable zinc available for total parenteral nutrition supplementation over the last 2 yea

239 they represent a major population requiring parenteral nutrition support for survival.

240 ea and failure to thrive, required prolonged parenteral nutrition support, and had high mortality.

241 ld promise as aids in restoring freedom from parenteral nutrition support; however, their long-term b

242 much higher serum insulin responses to total parenteral nutrition than with enteral nutrition that ap

243 ctors influence survival of patients on home parenteral nutrition, the costs related to this therapy,

244 that hepatic steatosis, which occurs during parenteral nutrition therapy, develops as a result of ch

245 e most devastating complication of long-term parenteral nutrition therapy.

246 9.2+/-0.8 days in the group receiving early parenteral nutrition; there was also a higher likelihood

247 d a few days after the child had weaned from parenteral nutrition to exclusive enteral tube feeding.

248 To assess the recent literature regarding parenteral nutrition to identify publications that have

249 There is no role for supplemental parenteral nutrition to increase caloric delivery in the

250 Copper supplementation is essential in parenteral nutrition to prevent an adverse effect of def

251 be in part responsible for the inability of parenteral nutrition to reduce proteolysis in preterm in

252 randomized controlled trial found that early parenteral nutrition to supplement insufficient enteral

253 al failure and require total or supplemental parenteral nutrition (TPN or PN, respectively).

254 Enteral nutrient deprivation via total parenteral nutrition (TPN) administration leads to local

255 o 60% of infants who require long-term total parenteral nutrition (TPN) for intestinal failure and 15

256 Total parenteral nutrition (TPN) is an invasive and advanced r

257 Total parenteral nutrition (TPN) is commonly used clinically t

258 Total parenteral nutrition (TPN) leads a loss of epithelial ba

259 d that enteral nutrient deprivation or total parenteral nutrition (TPN) led to a loss of intestinal e

260 roplasty [STEP]) in terms of survival, total parenteral nutrition (TPN) weaning, and complications.

261 l early enteral nutrition (NJEEN) with total parenteral nutrition (TPN), after pancreaticoduodenectom

262 al interest, with special reference to total parenteral nutrition (TPN), an area in which I have been

263 d antifungals, and ICU factors such as total parenteral nutrition (TPN), blood product transfusions,

264 n several models, including rats given total parenteral nutrition (TPN), IGF-I more potently stimulat

265 We utilized a model of total parenteral nutrition (TPN), or enteral nutrient deprivat

266 el of enteral nutrient deprivation, or total parenteral nutrition (TPN), resulting in intestinal muco

267 Mice that received total parenteral nutrition (TPN), which deprives the animals o

268 ailure patients do well with long-term total parenteral nutrition (TPN), while others develop life-th

269 Total parenteral nutrition (TPN), with the complete removal of

270 He recovered from PTLD but developed total parenteral nutrition (TPN)-induced liver failure.

271 of gut failure (GF) with the need for total parenteral nutrition (TPN).

272 itation with either jejunal tube feedings or parenteral nutrition until weight gain results in relief

273 judicious jejunostomy tube feeding, or total parenteral nutrition usage may reduce morbidity.

274 d with improved 60-day survival; conversely, parenteral nutrition use was associated with higher mort

275 Is parenteral nutrition via peripherally inserted central c

276 Compared with short peripheral cannulas, parenteral nutrition via PICCs is associated with better

277 hospital blood glucose concentration during parenteral nutrition was 129 +/- 14 mg/dL, without diffe

278 ars, and time from ITx to cessation of total parenteral nutrition was 31 days.

279 ent in protein and calories when appropriate parenteral nutrition was added to enteral sources.

280 Late parenteral nutrition was also associated with lower plas

281 Late parenteral nutrition was associated with a shorter durat

282 Early parenteral nutrition was given as control nutrition to o

283 tients receiving early parenteral nutrition, parenteral nutrition was initiated within 24 hours after

284 atients receiving late parenteral nutrition, parenteral nutrition was not provided until the morning

285 Parenteral nutrition was slowly tapered while increasing

286 se as survival, macronutrient absorption and parenteral nutrition weaning are improved after autologo

287 ety and efficacy of teduglutide as an aid to parenteral nutrition weaning.

288 percentages of infants who depended on total parenteral nutrition were 17 of 36 (47.2 percent) in the

289 -chain triglyceride, olive, and fish oils in parenteral nutrition were compared using an adjusted Cox

290 ic use in patients also receiving enteral or parenteral nutrition were included in the review.

291 r size larger than 10 cm, and need for total parenteral nutrition were shown to further define surviv

292 EPaNIC]), which compared early initiation of parenteral nutrition when enteral nutrition was insuffic

293 modeled was the probability of weaning from parenteral nutrition while on teduglutide.

294 upports increased supplementation of preterm parenteral nutrition with both choline and PUFAs.

295 Patients received total parenteral nutrition with standard (1.5 g . kg(-1) . day

296 en enteral nutrition was insufficient (early parenteral nutrition) with tolerating a pronounced nutri

297 and a need for opioid analgesic and enteral/parenteral nutrition, with an effect on patient survival

298 alue (hypocaloric) via enteral tube feeds or parenteral nutrition, with an equal protein allocation i

299 ddition to their routine care, compared with parenteral nutrition without omega-3 fatty acid suppleme

300 ur because of poor dietary intake, long-term parenteral nutrition without supplementation, and entera